RCMI Coordinating Center (RCMI CC) Header Logo

Anil Shanker

TitleDr
InstitutionMeharry Medical College
DepartmentBiochemistry, Cancer Biology, Neuroscience and Pharmacology
AddressLaboratory of Lymphocyte Function
2005 WBS Bldg, Meharry Medical College
Nashville TN 37208
Phone615 327 6460
Fax615 327 6442
vCardDownload vCard
    Other Positions
    TitleMember
    InstitutionVanderbilt-Ingram Comprehensive Cancer Center
    DepartmentHost-Tumor Interactions Research Program


    Collapse Biography 
    Collapse awards and honors
    2012Pilot Project initiative in the NCI SPORE in Lung Cancer (5P50 CA 090949), : NIH
    2011Meharry Translational Research Center Pilot Grant in 5U54RR026140, : NIH
    2011Minority-Serving Institution Faculty Scholar in Cancer Research Award, : AACR
    2008Fellows Award for Research Excellence, : NIH
    2006Fellows Award for Research Excellence, : NIH
    2005International Cancer Technology Transfer Grant, : IUAC
    2006NIH Award of Merit, : NCI
    2012Early Career Faculty Travel Grant, : AAI
    2011Minority-Serving Institution Faculty Scholar Award in Cancer Prevention Research, : AACR
    2013 - 2017SCORE SC1 award, : NCI
    2013Minority-Serving Institution Faculty Scholar in Cancer Research Award, : AACR
    2014Society for Immunotherapy of Cancer Award

    Collapse Overview 
    Collapse overview
    Dr. Anil Shanker leads the Laboratory of Lymphocyte Function in the Department of Biochemistry and Cancer Biology at Meharry Medical College School of Medicine. He is also a member of the Host-Tumor Interactions Research Program of Vanderbilt-Ingram Comprehensive Cancer Center (VICC) at Vanderbilt University. After completing his Master’s degree in Zoology/Cell Biology at the University of Delhi, Dr. Shanker obtained his PhD in tumor immunobiology from Banaras Hindu University, India in 1999. He performed his postdoctoral studies in tumor immunology at the CNRS/INSERM Center of Immunology (CIML), Marseille, France from 2000 to 2003, and at the National Cancer Institute, Frederick, Maryland from 2003 to 2008. He worked as Scientist I in the Cancer and Inflammation Program at the NCI from 2008 to 2010, before joining as faculty at Meharry Medical College.
    The Shanker laboratory studies information processing and molecular circuitry underlying lymphocyte crosstalk. Using the TCR-transgenic mice specific to cancer-germline self-antigen P1A, akin to human MAGE antigens (J Immunol 172:5069), our pioneering studies discovered a paradigm of CD8 T cell help for innate NK effector function in solid tumor microenvironments. Such a potentiated CD8 T–NK crosstalk enhances immunosurveillance against tumor development and prevents tumor escape (J Immunol 179:6377). Our ongoing work has identified mitochondrial Ca2+ transport-mediated intermembranous interaction critical during CD8 T–NK cooperativity to elicit NK cell effector/regulatory and T cell memory functions. We also found that CD8 T cells preferentially use death ligands to clear metastasis of tumor cells expressing low-avidity antigens (Cancer Res 69:6615). These findings provide for novel immunotherapy approaches that we are exploring to prevent tumor development, escape and metastasis. In breast, kidney and inducible EGFR-mutant lung cancer mouse models, and patient samples in a multi-institutional collaboration, we are testing adoptive transfer protocols of CD8 T and NK cells in combination with engineered Notch ligand constructs (Cancer Res 71:6122, 75:4728; JITC 7:95), bortezomib, a proteasome inhibitor (J Immunol 180:163; JNCI 100:649; Cancer Res 75:5260), and neurotransmitter agonists. Our efforts are also invested in building computational models that guide cell fate and lymphocyte functional crosstalk (Open Biol 6:160192; Front Immunol 10:1906). The laboratory provides a vibrant research environment for mentoring its undergrad, doctoral, postdoctoral and medical trainees from diverse backgrounds.

    Collapse Research 
    Collapse research activities and funding
    SC1CA182843     (SHANKER, ANIL)Jul 12, 2013 - Jun 30, 2017
    NIH/NCI
    Immunomodulatory effects of bortezomib on antitumor CD8 T-NK cell crosstalk
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Srivastava RM, Marincola FM, Shanker A. Editorial: Lymphocyte Functional Crosstalk and Regulation. Front Immunol. 2019; 10:2916. PMID: 31921175.
      Citations:    Fields:    
    2. Uzhachenko RV, Shanker A. CD8+ T Lymphocyte and NK Cell Network: Circuitry in the Cytotoxic Domain of Immunity. Front Immunol. 2019; 10:1906. PMID: 31456803.
      Citations: 1     Fields:    
    3. Tchekneva EE, Goruganthu MUL, Uzhachenko RV, Thomas PL, Antonucci A, Chekneva I, Koenig M, Piao L, Akhter A, de Aquino MTP, Ranganathan P, Long N, Magliery T, Valujskikh A, Evans JV, Arasada RR, Massion PP, Carbone DP, Shanker A, Dikov MM. Correction to: Determinant roles of dendritic cell-expressed Notch Delta-like and Jagged ligands on anti-tumor T-cell immunity. J Immunother Cancer. 2019 May 07; 7(1):124. PMID: 31064404.
      Citations:    Fields:    
    4. Tchekneva EE, Goruganthu MUL, Uzhachenko RV, Thomas PL, Antonucci A, Chekneva I, Koenig M, Piao L, Akhter A, de Aquino MTP, Ranganathan P, Long N, Magliery T, Valujskikh A, Evans JV, Arasada RR, Massion PP, Carbone DP, Shanker A, Dikov MM. Determinant roles of dendritic cell-expressed Notch Delta-like and Jagged ligands on anti-tumor T cell immunity. J Immunother Cancer. 2019 04 02; 7(1):95. PMID: 30940183.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    5. Renrick AN, Dunbar ZT, Shanker A. Update on the current revolution in cancer immunotherapy. Immunotherapy. 2019 01; 11(1):15-20. PMID: 30702010.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    6. Shanker A, Thounaojam MC, Mishra MK, Dikov MM. Innate-Adaptive Immune Crosstalk 2016. J Immunol Res. 2017; 2017:3503207. PMID: 28491874.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    7. Uzhachenko R, Boyd K, Olivares-Villagomez D, Zhu Y, Goodwin JS, Rana T, Shanker A, Tan WJ, Bondar T, Medzhitov R, Ivanova AV. Mitochondrial protein Fus1/Tusc2 in premature aging and age-related pathologies: critical roles of calcium and energy homeostasis. Aging (Albany NY). 2017 03 26; 9(3):627-649. PMID: 28351997.
      Citations: 4     Fields:    Translation:AnimalsCells
    8. Pellom ST, Singhal A, Shanker A. Prospects of combining adoptive cell immunotherapy with bortezomib. Immunotherapy. 2017 03; 9(4):305-308. PMID: 28303766.
      Citations:    Fields:    Translation:HumansAnimalsCells
    9. Pellom ST, Dudimah DF, Thounaojam MC, Uzhachenko RV, Singhal A, Richmond A, Shanker A. Bortezomib augments lymphocyte stimulatory cytokine signaling in the tumor microenvironment to sustain CD8+T cell antitumor function. Oncotarget. 2017 Jan 31; 8(5):8604-8621. PMID: 28052005.
      Citations: 2     Fields:    Translation:AnimalsCells
    10. Uzhachenko R, Shanker A, Dupont G. Computational properties of mitochondria in T cell activation and fate. Open Biol. 2016 11; 6(11). PMID: 27852805.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    11. Lawrence S, Pellom ST, Shanker A, Whalen MM. Tributyltin exposure alters cytokine levels in mouse serum. J Immunotoxicol. 2016 11; 13(6):870-878. PMID: 27602597.
      Citations: 1     Fields:    Translation:HumansAnimals
    12. Pulliam SR, Pellom ST, Shanker A, Adunyah SE. Butyrate regulates the expression of inflammatory and chemotactic cytokines in human acute leukemic cells during apoptosis. Cytokine. 2016 08; 84:74-87. PMID: 27253488.
      Citations:    Fields:    Translation:HumansCells
    13. Uzhachenko R, Shanker A. Notching tumor: Signaling through Notch receptors improves antitumor T cell immunity. Oncoimmunology. 2016 May; 5(5):e1122864. PMID: 27467934.
      Citations:    
    14. Clark RS, Pellom ST, Booker B, Ramesh A, Zhang T, Shanker A, Maguire M, Juarez PD, Patricia MJ, Langston MA, Lichtveld MY, Hood DB. Validation of research trajectory 1 of an Exposome framework: Exposure to benzo(a)pyrene confers enhanced susceptibility to bacterial infection. Environ Res. 2016 Apr; 146:173-84. PMID: 26765097.
      Citations: 3     Fields:    Translation:HumansCells
    15. Pulliam SR, Uzhachenko RV, Adunyah SE, Shanker A. Common gamma chain cytokines in combinatorial immune strategies against cancer. Immunol Lett. 2016 Jan; 169:61-72. PMID: 26597610.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    16. Shanker A, Thounaojam MC, Mishra MK, Dikov MM, Uzhachenko RV. Innate-Adaptive Immune Crosstalk. J Immunol Res. 2015; 2015:982465. PMID: 26618182.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    17. Shanker A, Pellom ST, Dudimah DF, Thounaojam MC, de Kluyver RL, Brooks AD, Yagita H, McVicar DW, Murphy WJ, Longo DL, Sayers TJ. Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity. Cancer Res. 2015 Dec 15; 75(24):5260-72. PMID: 26494122.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    18. Thounaojam MC, Dudimah DF, Pellom ST, Uzhachenko RV, Carbone DP, Dikov MM, Shanker A. Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-?B crosstalk. Oncotarget. 2015 Oct 20; 6(32):32439-55. PMID: 26431276.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    19. Biktasova AK, Dudimah DF, Uzhachenko RV, Park K, Akhter A, Arasada RR, Evans JV, Novitskiy SV, Tchekneva EE, Carbone DP, Shanker A, Dikov MM. Multivalent Forms of the Notch Ligand DLL-1 Enhance Antitumor T-cell Immunity in Lung Cancer and Improve Efficacy of EGFR-Targeted Therapy. Cancer Res. 2015 Nov 15; 75(22):4728-41. PMID: 26404003.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    20. Shanker A, Dikov MM, Carbone DP. Promise of Immunotherapy in Lung Cancer. Prog Tumor Res. 2015; 42:95-109. PMID: 26383097.
      Citations:    Fields:    Translation:HumansAnimals
    21. Pellom ST, Dudimah DF, Thounaojam MC, Sayers TJ, Shanker A. Modulatory effects of bortezomib on host immune cell functions. Immunotherapy. 2015; 7(9):1011-22. PMID: 26325610.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    22. Uzhachenko R, Shanker A, Yarbrough WG, Ivanova AV. Mitochondria, calcium, and tumor suppressor Fus1: At the crossroad of cancer, inflammation, and autoimmunity. Oncotarget. 2015 Aug 28; 6(25):20754-72. PMID: 26246474.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    23. de Aquino MT, Malhotra A, Mishra MK, Shanker A. Challenges and future perspectives of T cell immunotherapy in cancer. Immunol Lett. 2015 Aug; 166(2):117-33. PMID: 26096822.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    24. Uzhachenko R, Ivanov SV, Yarbrough WG, Shanker A, Medzhitov R, Ivanova AV. Fus1/Tusc2 is a novel regulator of mitochondrial calcium handling, Ca2+-coupled mitochondrial processes, and Ca2+-dependent NFAT and NF-?B pathways in CD4+ T cells. Antioxid Redox Signal. 2014 Apr 01; 20(10):1533-47. PMID: 24328503.
      Citations: 13     Fields:    Translation:AnimalsCells
    25. Ascierto ML, Idowu MO, Zhao Y, Khalak H, Payne KK, Wang XY, Dumur CI, Bedognetti D, Tomei S, Ascierto PA, Shanker A, Bear HD, Wang E, Marincola FM, De Maria A, Manjili MH. Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients. J Transl Med. 2013 Jun 12; 11:145. PMID: 23758773.
      Citations: 23     Fields:    Translation:HumansCells
    26. Shanker A. “Tuning NOTCH”. J Blood Lymph. doi:10.4172/2165-7831.1000e112 . 2013; (3):e112.
    27. Pellom ST, Shanker A. Development of Proteasome Inhibitors as Therapeutic Drugs. J Clin Cell Immunol. 2012 Mar 15; S5:5. PMID: 23338480.
      Citations:    
    28. Shanker A. “Lymphocyte Teamwork in Tumor Rejection”. In “Prospects in Bioscience: Addressing the issues”, ed. Sabu A and Augustine A, Springer, p. 49-56 – Book Chapter. 2012; (3).
    29. Malhotra A, Shanker A. NK cells: immune cross-talk and therapeutic implications. Immunotherapy. 2011 Oct; 3(10):1143-66. PMID: 21995569.
      Citations: 25     Fields:    Translation:HumansAnimalsCells
    30. Huang Y, Lin L, Shanker A, Malhotra A, Yang L, Dikov MM, Carbone DP. Resuscitating cancer immunosurveillance: selective stimulation of DLL1-Notch signaling in T cells rescues T-cell function and inhibits tumor growth. Cancer Res. 2011 Oct 01; 71(19):6122-31. PMID: 21825014.
      Citations: 27     Fields:    Translation:HumansAnimalsCells
    31. Shanker A, Marincola FM. Cooperativity of adaptive and innate immunity: implications for cancer therapy. Cancer Immunol Immunother. 2011 Aug; 60(8):1061-74. PMID: 21656157.
      Citations: 13     Fields:    Translation:HumansAnimals
    32. Shanker A. “Neuroendocrine Crosstalk of Immunity”. J Blood Lymph. doi:10.4172/jbl.1000e105 . 2011; 1(1):e105.
    33. Brooks AD, Jacobsen KM, Li W, Shanker A, Sayers TJ. Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex. Mol Cancer Res. 2010 May; 8(5):729-38. PMID: 20442297.
      Citations: 26     Fields:    Translation:HumansCells
    34. Shanker A. Adaptive control of innate immunity. Immunol Lett. 2010 Jul 08; 131(2):107-12. PMID: 20394777.
      Citations: 3     Fields:    Translation:HumansAnimals
    35. Shanker A, Buferne M, Schmitt-Verhulst AM. Cooperative action of CD8 T lymphocytes and natural killer cells controls tumour growth under conditions of restricted T-cell receptor diversity. Immunology. 2010 Jan; 129(1):41-54. PMID: 20050329.
      Citations: 12     Fields:    Translation:AnimalsCells
    36. Shanker A. “The Immune Rejection: Lessons from Experimental Models”. In “Immunologic Signatures of Rejection”, ed. Marincola FM and Wang E, Springer, NY, p. 17-26 – Book Chapter DOI 10.1007/978-1-4419-7219-4_3 . 2010.
    37. Shanker A, Brooks AD, Jacobsen KM, Wine JW, Wiltrout RH, Yagita H, Sayers TJ. Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity. Cancer Res. 2009 Aug 15; 69(16):6615-23. PMID: 19654302.
      Citations: 15     Fields:    Translation:AnimalsCells
    38. Shanker A, Brooks AD, Tristan CA, Wine JW, Elliott PJ, Yagita H, Takeda K, Smyth MJ, Murphy WJ, Sayers TJ. Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody. J Natl Cancer Inst. 2008 May 07; 100(9):649-62. PMID: 18445820.
      Citations: 42     Fields:    Translation:HumansAnimalsCells
    39. Hallett WH, Ames E, Motarjemi M, Barao I, Shanker A, Tamang DL, Sayers TJ, Hudig D, Murphy WJ. Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. J Immunol. 2008 Jan 01; 180(1):163-70. PMID: 18097016.
      Citations: 60     Fields:    Translation:AnimalsCells
    40. Shanker A, Verdeil G, Buferne M, Inderberg-Suso EM, Puthier D, Joly F, Nguyen C, Leserman L, Auphan-Anezin N, Schmitt-Verhulst AM. CD8 T cell help for innate antitumor immunity. J Immunol. 2007 Nov 15; 179(10):6651-62. PMID: 17982055.
      Citations: 33     Fields:    Translation:AnimalsCells
    41. Shanker A, Sayers T. Sensitizing tumor cells to immune-mediated cytotoxicity. Adv Exp Med Biol. 2007; 601:163-71. PMID: 17713003.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    42. Abdool K, Cretney E, Brooks AD, Kelly JM, Swann J, Shanker A, Bere EW, Yokoyama WM, Ortaldo JR, Smyth MJ, Sayers TJ. NK cells use NKG2D to recognize a mouse renal cancer (Renca), yet require intercellular adhesion molecule-1 expression on the tumor cells for optimal perforin-dependent effector function. J Immunol. 2006 Aug 15; 177(4):2575-83. PMID: 16888019.
      Citations: 9     Fields:    Translation:AnimalsCells
    43. Cretney E, Shanker A, Yagita H, Smyth MJ, Sayers TJ. TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer. Immunol Cell Biol. 2006 Feb; 84(1):87-98. PMID: 16405656.
      Citations: 28     Fields:    Translation:HumansAnimals
    44. Shanker A, Auphan-Anezin N, Chomez P, Giraudo L, Van den Eynde B, Schmitt-Verhulst AM. Thymocyte-intrinsic genetic factors influence CD8 T cell lineage commitment and affect selection of a tumor-reactive TCR. J Immunol. 2004 Apr 15; 172(8):5069-77. PMID: 15067090.
      Citations: 7     Fields:    Translation:AnimalsCells
    45. Shanker A. Is thymus redundant after adulthood? Immunol Lett. 2004 Feb 15; 91(2-3):79-86. PMID: 15019273.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    46. Shrivastav A, Singh NK, Singh SB, Singh SM, Singh N, Shanker A. Antitumor effect of some 3d-metal complexes of N-isonicotinoyl-N'-o-hydroxythiobenzhydrazide. Bioinorg Chem Appl. 2003; 255-70. PMID: 18365058.
      Citations:    
    47. Shanker A, Singh SM. Immunopotentiation in mice bearing a spontaneous transplantable T-cell lymphoma: role of thymic extract. Neoplasma. 2003; 50(4):272-9. PMID: 12937840.
      Citations: 1     Fields:    Translation:AnimalsCells
    48. Shanker A, Singh SM, Sodhi A. Ascitic growth of a spontaneous transplantable T cell lymphoma induces thymic involution. 2. Induction of apoptosis in thymocytes. Tumour Biol. 2000 Nov-Dec; 21(6):315-27. PMID: 11006572.
      Citations: 2     Fields:    Translation:AnimalsCells
    49. Shanker A, Singh SM, Sodhi A. Ascitic growth of a spontaneous transplantable T cell lymphoma induces thymic involution. 1. Alterations in the CD4/CD8 distribution in thymocytes. Tumour Biol. 2000 Sep-Oct; 21(5):288-98. PMID: 10940825.
      Citations: 7     Fields:    Translation:AnimalsCells
    50. Roy R, Singh SM, Shanker A, Sodhi A. Mechanism of thymocyte apoptosis induced by serum of tumor-bearing host: the molecular events involved and their inhibition by thymosin alpha-1. Int J Immunopharmacol. 2000 Apr; 22(4):309-21. PMID: 10689104.
      Citations: 3     Fields:    Translation:AnimalsCells
    51. Shanker A, Singh SM, Sodhi A. Impairment of T-cell functions with the progressive ascitic growth of a transplantable T-cell lymphoma of spontaneous origin. FEMS Immunol Med Microbiol. 2000 Mar; 27(3):247-55. PMID: 10683470.
      Citations: 1     Fields:    Translation:AnimalsCells
    52. Shanker A, Singh SM. Characterization of factors inducing apoptosis in thymocytes of mice bearing a transplantable T-cell lymphoma of spontaneous origin. Neoplasma. 2000; 47(2):90-5. PMID: 10985473.
      Citations: 1     Fields:    Translation:Animals
    Shanker's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (246)
    Explore
    _
    Co-Authors (3)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

    For technical support please contact support